A new approach of anti-PD1 immunotherapy (atezolizumab) combined with bevacizumab (an agent that blocks the growth of new blood vessels therefore limiting the supply of…
A phase 2 immunotherapy clinical trial combining durvalumab, an immunotherapy drug, with standard treatment of Alimta (pemetrexed)/cisplatin has shown promising overall survival results. The study enrolled 55 patients and…
In 2016, the Mesothelioma Applied Research Foundation funded a grant to Antonio Giordano, MD, PhD, director and founder of the Sbarro Health Research Organization at Temple University, to investigate how silencing…
A white paper documenting presentations and discussions from the Mesothelioma Patient Registry workshop, which was convened by the Mesothelioma Applied Research Foundation in March of…
In late August, the Mesothelioma Applied Research Foundation hosted an interview as part of its Meet the Mesothelioma Experts (MTME) series to discuss a new…
The New York Proton Center, the first proton therapy facility to open in the state of New York, began treating patients at its state-of-the-art East…
On July 24, 2019, the Mesothelioma Applied Research Foundation hosted Michael Harbut, MD, on our Meet the Mesothelioma Experts (MTME) live broadcast, where he discussed…
On Wednesday, July 24, 2019, at 8:00 PM EDT, the Meso Foundation’s Meet the Mesothelioma Experts live broadcast will feature Michael Harbut, MD. Dr. Harbut will…
Despite initial positive signs from its phase 2 counterpart, the phase 3 LUME-Meso trial in malignant pleural mesothelioma did not meet its primary endpoint of…
The short answer is: no. Maintenance pemetrexed (Alimta) following standard treatment of pemetrexed (Alimta)/cisplatin does not prolong progression-free survival in patients with pleural mesothelioma. It…